中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

胸膜腔内注射聚桂醇治疗难治性肝性胸水1例报告

李常洲 李建辉 郝欣 姜海斌 王爱民 花海洋 齐静 张静哲

引用本文:
Citation:

胸膜腔内注射聚桂醇治疗难治性肝性胸水1例报告

DOI: 10.3969/j.issn.1001-5256.2021.09.033
基金项目: 

2019年度河北省医学科学研究课题计划 (20191297)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:李常洲负责文献检索、资料收集分析及论文撰写;李建辉负责课题设计、论文修改及最后定稿;郝欣、姜海斌、王爱民、花海洋、齐静、张静哲负责文献的搜索、分析和整理。
详细信息
    通信作者:

    李建辉,changzhou20@126.com

  • 中图分类号: R561

Treatment of refractory hepatic hydrothorax by intrapleural injection of lauromacrogol: A case report

Research funding: 

Hebei Medical Science Research Project 2019 (20191297)

  • 图  1  2017年10月5日胸部CT

    注:a, 冠状位;b,横断位(纵隔窗)。右侧大量胸腔积液,局部肺不张。

    图  2  2017年12月10日胸部CT

    注:a,冠状位;b,横断位(肺窗)。右侧大量胸腔积液、右肺不张。

    图  3  2017年12月15日胸部CT

    注:经胸腔引流管充分引流后见胸腔积液已明显减少,右肺复张。

    图  4  2017年12月22日(术后1周)胸部及腹部CT

    注:a,横断位(纵隔窗);b,横断位(肺窗);c,腹部CT。仅见右肺叶间裂少量积液,右肺中叶膨胀不好,右肺上下叶均复张较好。

    图  5  2018年1月24日胸部及腹部CT

    注:a,冠状位;b,横断位(纵隔窗);c,横断位(肺窗);d,腹部CT。胸腔积液已消失,右肺膨胀良好,同时腹水也明显减少。

  • [1] AL-ZOUBI RK, ABU GHANIMEH M, GOHAR A, et al. Hepatic hydrothorax: Clinical review and update on consensus guidelines[J]. Hosp Pract (1995), 2016, 44(4): 213-223. DOI: 10.1080/21548331.2016.1227685.
    [2] SUÁREZ PM, GILART JL. Pleurodesis in the treatment of pneumothorax and pleural effusion[J]. Monaldi Arch Chest Dis, 2013, 79(2): 81-86. DOI: 10.4081/monaldi.2013.96.
    [3] ZAHID I, ROUTLEDGE T, BILLÈ A, et al. What is the best treatment for malignant pleural effusions?[J]. Interact Cardiovasc Thorac Surg, 2011, 12(5): 818-823. DOI: 10.1510/icvts.2010.254789.
    [4] RODRIGUEZ-PANADERO F, MONTES-WORBOYS A. Mechanisms of pleurodesis[J]. Respiration, 2012, 83(2): 91-98. DOI: 10.1159/000335419.
    [5] AGARWAL R, KHAN A, AGGARWAL AN, et al. Efficacy & safety of iodopovidone pleurodesis: A systematic review & meta-analysis[J]. Indian J Med Res, 2012, 135: 297-304.
    [6] CHAI Y, ZHOU Z, SONG J, et al. Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas[J]. J Dermatol, 2019, 46(9): 770-776. DOI: 10.1111/1346-8138.14992.
    [7] SCHIBLER F, BORRADORI L, RAMELET AA. Subcutaneous injection of large volumes of polidocanol[J]. Dermatol Surg, 2019, 45(3): 476-477. DOI: 10.1097/DSS.0000000000001544.
    [8] TU CY, CHEN CH. Spontaneous bacterial empyema[J]. Curr Opin Pulm Med, 2012, 18(4): 355-358. DOI: 10.1097/MCP.0b013e328352b50f.
    [9] NORVELL JP, SPIVEY JR. Hepatic hydrothorax[J]. Clin Liver Dis, 2014, 18(2): 439-449. DOI: 10.1016/j.cld.2014.01.005.
    [10] WINTER H, DRÄGER E, STERRY W. Sclerotherapy for treatment of hemangiomas[J]. Dermatol Surg, 2000, 26(2): 105-108. DOI: 10.1046/j.1524-4725.2000.98012.x.
    [11] GROVER C, KHURANA A, BHATTACHARYA SN. Sclerotherapy for the treatment of infantile hemangiomas[J]. J Cutan Aesthet Surg, 2012, 5(3): 201-203. DOI: 10.4103/0974-2077.101383.
    [12] TREMBLAY A, STATHER DR, KELLY MM. Effect of repeated administration of low-dose silver nitrate for pleurodesis in a rabbit model[J]. Respirology, 2011, 16(7): 1070-1075. DOI: 10.1111/j.1440-1843.2011.02007.x.
    [13] CHEN Y, LI C, XU L, et al. Novel treatment for chylothorax after esophagectomy with 50% glucose pleurodesis[J]. Ann Vasc Surg, 2010, 24(5): 694. e9-e13. DOI: 10.1016/j.avsg.2009.10.021.
    [14] FUJINO K, MOTOOKA Y, KOGA T, et al. Novel approach to pleurodesis with 50% glucose for air leakage after lung resection or pneumothorax[J]. Surg Today, 2016, 46(5): 599-602. DOI: 10.1007/s00595-015-1223-2.
    [15] ROUSSOS A, PHILIPPOU N, MANTZARIS GJ, et al. Hepatic hydrothorax: Pathophysiology diagnosis and management[J]. J Gastroenterol Hepatol, 2007, 22(9): 1388-1393. DOI: 10.1111/j.1440-1746.2007.05069.x.
    [16] BADILLO R, ROCKEY DC. Hepatic hydrothorax: Clinical features, management, and outcomes in 77 patients and review of the literature[J]. Medicine (Baltimore), 2014, 93(3): 135-142. DOI: 10.1097/MD.0000000000000025.
    [17] KIAFAR C, GILANI N. Hepatic hydrothorax: Current concepts of pathophysiology and treatment options[J]. Ann Hepatol, 2008, 7(4): 313-320. http://www.annalsofhepatology.com/PDF/vol7n4/Hp084-02.pdf
    [18] LIEBERMAN FL, HIDEMURA R, PETERS RL, et al. Pathogenesis and treatment of hydrothorax complicating cirrhosis with ascites[J]. Ann Intern Med, 1966, 64(2): 341-351. DOI: 10.7326/0003-4819-64-2-341.
    [19] YALCIN NG, CHOONG CK, EIZENBERG N. Anatomy and pathophysiology of the pleura and pleural space[J]. Thorac Surg Clin, 2013, 23(1): 1-10. DOI: 10.1016/j.thorsurg.2012.10.008.
    [20] LV Y, HAN G, FAN D. Hepatic hydrothorax[J]. Ann Hepatol, 2018, 17(1): 33-46. DOI: 10.5604/01.3001.0010.7533.
    [21] VILLENA GARRIDO V, CASES VIEDMA E, FERNÁNDEZ VILLAR A, et al. Recommendations of diagnosis and treatment of pleural effusion. Update[J]. Arch Bronconeumol, 2014, 50(6): 235-249. DOI: 10.1016/j.arbres.2014.01.016.
    [22] BORCHARDT J, SMIRNOV A, METCHNIK L, et al. Treating hepatic hydrothorax[J]. BMJ, 2003, 326(7392): 751-752. DOI: 10.1136/bmj.326.7392.751.
    [23] SINGH A, BAJWA A, SHUJAAT A. Evidence-based review of the management of hepatic hydrothorax[J]. Respiration, 2013, 86(2): 155-173. DOI: 10.1159/000346996.
    [24] LEE WJ, KIM HJ, PARK JH, et al. Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis[J]. Korean J Hepatol, 2011, 17(4): 292-298. DOI: 10.3350/kjhep.2011.17.4.292.
    [25] FELLER-KOPMAN D, LIGHT R. Pleural disease[J]. N Engl J Med, 2018, 378(8): 740-751. DOI: 10.1056/NEJMra1403503.
    [26] WEST JB. Snorkel breathing in the elephant explains the unique anatomy of its pleura[J]. Respir Physiol, 2001, 126(1): 1-8. DOI: 10.1016/s0034-5687(01)00203-1.
    [27] WEST JB. Why doesn't the elephant have a pleural space?[J]. News Physiol Sci, 2002, 17: 47-50. DOI: 10.1152/nips.01374.2001.
    [28] MIERZEJEWSKI M, KORCZYNSKI P, KRENKE R, et al. Chemical pleurodesis - a review of mechanisms involved in pleural space obliteration[J]. Respir Res, 2019, 20(1): 247. DOI: 10.1186/s12931-019-1204-x.
    [29] STRUNK H, MARINOVA M. Transjugular Intrahepatic Portosystemic Shunt (TIPS): Pathophysiologic basics, actual indications and results with review of the literature[J]. Rofo, 2018, 190(8): 701-711. DOI: 10.1055/a-0628-7347.
    [30] DHANASEKARAN R, WEST JK, GONZALES PC, et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis[J]. Am J Gastroenterol, 2010, 105(3): 635-641. DOI: 10.1038/ajg.2009.634.
    [31] VIZZUTTI F, SCHEPIS F, ARENA U, et al. Transjugular intrahepatic portosystemic shunt (TIPS): Current indications and strategies to improve the outcomes[J]. Intern Emerg Med, 2020, 15(1): 37-48. DOI: 10.1007/s11739-019-02252-8.
  • 加载中
图(5)
计量
  • 文章访问数:  284
  • HTML全文浏览量:  55
  • PDF下载量:  29
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-01-22
  • 录用日期:  2021-02-15
  • 出版日期:  2021-09-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回